FRANCISCO GARCIA SORIANO
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Clínica Médica, Faculdade de Medicina - Docente
LIM/51 - Laboratório de Emergências Clínicas, Hospital das Clínicas, Faculdade de Medicina - Líder
LIM/51 - Laboratório de Emergências Clínicas, Hospital das Clínicas, Faculdade de Medicina - Líder
2 resultados
Resultados de Busca
Agora exibindo 1 - 2 de 2
- Intensive glucose control in critically ill adults: a protocol for a systematic review and individual patient data meta-analysis(2023) ADIGBLI, D.; YANG, L.; HAMMOND, N.; ANNANE, D.; ARABI, Y.; BILOTTA, F.; BOHé, J.; BRUNKHORST, F. M.; CAVALCANTI, A. B.; COOK, D.; ENGEL, C.; GREEN-LAROCHE, D.; HE, W.; HENDERSON, W.; HOEDEMAEKERS, C.; IAPICHINO, G.; KALFON, P.; ROSA, G. de La; MACKENZIE, I.; MéLOT, C.; MITCHELL, I.; OKSANEN, T.; POLLI, F.; PREISER, J.-C.; SORIANO, F. G.; WANG, L.-C.; YUAN, J.; DELANEY, A.; TANNA, G. L. D.; FINFER, S.Objective: The optimal target for blood glucose concentration in critically ill patients is unclear. We will perform a systematic review and meta-analysis with aggregated and individual patient data from randomized controlled trials, comparing intensive glucose control with liberal glucose control in critically ill adults. Data sources: MEDLINE®, Embase, the Cochrane Central Register of Clinical Trials, and clinical trials registries (World Health Organization, clinical trials.gov). The authors of eligible trials will be invited to provide individual patient data. Published trial-level data from eligible trials that are not at high risk of bias will be included in an aggregated data meta-analysis if individual patient data are not available. Methods: Inclusion criteria: randomized controlled trials that recruited adult patients, targeting a blood glucose of ≤ 120mg/dL (≤ 6.6mmol/L) compared to a higher blood glucose concentration target using intravenous insulin in both groups. Excluded studies: those with an upper limit blood glucose target in the intervention group of > 120mg/ dL (> 6.6mmol/L), or where intensive glucose control was only performed in the intraoperative period, and those where loss to follow-up exceeded 10% by hospital discharge. Primary endpoint: In-hospital mortality during index hospital admission. Secondary endpoints: mortality and survival at other timepoints, duration of invasive mechanical ventilation, vasoactive agents, and renal replacement therapy. A random effect Bayesian meta-analysis and hierarchical Bayesian models for individual patient data will be used. Discussion: This systematic review with aggregate and individual patient data will address the clinical question, ‘what is the best blood glucose target for critically ill patients overall?’.
- Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases(2018) BERGER, Nathan A.; BESSON, Valerie C.; BOULARES, A. Hamid; BURKLE, Alexander; CHIARUGI, Alberto; CLARK, Robert S.; CURTIN, Nicola J.; CUZZOCREA, Salvatore; DAWSON, Ted M.; DAWSON, Valina L.; HASKO, Gyorgy; LIAUDET, Lucas; MORONI, Flavio; PACHER, Pal; RADERMACHER, Peter; SALZMAN, Andrew L.; SNYDER, Solomon H.; SORIANO, Francisco Garcia; STROSZNAJDER, Robert P.; SUMEGI, Balazs; SWANSON, Raymond A.; SZABO, CsabaThe recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for potential therapeutic repurposing for non-oncological indications. Considering (a) the preclinical efficacy data with PARP inhibitors in non-oncological diseases and (b) the risk-benefit ratio of treating patients with a compound that inhibits an enzyme that has physiological roles in the regulation of DNA repair, we have selected indications, where (a) the severity of the disease is high, (b) the available therapeutic options are limited, and (c) the duration of PARP inhibitor administration could be short, to provide first-line options for therapeutic repurposing. These indications are as follows: acute ischaemic stroke; traumatic brain injury; septic shock; acute pancreatitis; and severe asthma and severe acute lung injury. In addition, chronic, devastating diseases, where alternative therapeutic options cannot halt disease development (e.g. Parkinson's disease, progressive multiple sclerosis or severe fibrotic diseases), should also be considered. We present a preclinical and clinical action plan for the repurposing of PARP inhibitors.